Regeneron completes trial enrollment for autoinflammatory disease treatment

By Elaine Rigoli

Tampa, Fla., April 19 - Regeneron Pharmaceuticals, Inc. has completed enrollment for its phase 3 trial for the treatment of CIAS1-associated periodic syndrome, a spectrum of very rare genetic disorders.

This orphan drug program is assessing the efficacy and safety of the Interleukin-1 (IL-1) Trap, a long-acting IL-1 inhibitor, in adult patients with these diseases characterized by spontaneous systemic inflammation.

IL-1 is a soluble protein secreted by certain cells in the body.

In many cases, IL-1 acts as a messenger to help regulate immune and inflammatory responses by attaching to cell-surface receptors in cells that participate in the body's immune system.

The trial will include a six-month, placebo-controlled efficacy phase and will be followed by a six-month, open-label extension phase, according to a news release.

The efficacy phase of this trial is expected to be completed by the end of 2006, the release said.

Tarrytown, N.Y.-based Regeneron is a biopharmaceutical company that discovers, develops and intends to commercialize therapeutic medicines for the treatment of serious medical conditions.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.